As we bid farewell to the old and usher in the new, we strive to achieve fruitful results

To further implement General Secretary Xi Jinping's important instructions on the social responsibility of private enterprises, implement the spirit of the 20th National Congress of the Communist Party of China and the Second and Third Plenary Sessions of the 20th Central Committee, and better guide private enterprises in fulfilling their social responsibilities, focusing on the "two healths" work theme, the All-China Federation of Industry and Commerce recently launched its highly anticipated 2024 "Outstanding Case Studies of Chinese Private Enterprise Social Responsibility." Based on recommendations from provincial federations of industry and commerce, and drawing on data from 13,885 participating private enterprises and publicly available information from relevant national departments, this comprehensive analysis of the social responsibility of Chinese private enterprises in 2023 was conducted. The selection focused on seven key areas: promoting scientific and technological innovation, accelerating green development, promoting stable employment, participating in rural revitalization, engaging in philanthropy, focusing on overseas responsibilities, and standardizing corporate governance. Among them, Fushine Pharmaceuticals' application, "Exploring New Fields in Microbial Proteins to Help Maintain Food Security," was selected as an outstanding case study in the "Science and Technology Innovation" category.

"Dare to enter the narrow gate, dare to go the long way." In recent years, the rapid population growth has spawned many daunting challenges, such as the growing demand for meat. Discovering more "new energy sources for food" and protein supply has become a major challenge that needs to be addressed. my country has introduced a number of policies to support the development of the artificial protein industry. The National Development and Reform Commission issued the "14th Five-Year Plan for the Development of the Bioeconomy," which explicitly states that the bioeconomy will become a new driving force for future corporate economic transformation. It also proposes exploring and developing new food products, such as "artificial protein," to achieve iterative upgrades in the food industry and reduce the environmental and resource pressures imposed by traditional animal husbandry.

In response to President Xi Jinping's "Big Food" vision at the Fifth Session of the 13th National Committee of the Chinese People's Political Consultative Conference, Fushine Pharmaceuticals is developing biotechnology and bioindustries, seeking to derive calories and protein from plants, animals, and microorganisms. In 2023, Fushine Pharmaceuticals rose to the challenge and expanded into synthetic biology microbial protein. Utilizing proprietary biofermentation technology, the company uses enzyme conversion technology to convert wastewater from microbial protein production into amino acid water-soluble fertilizer that meets national standards. This, while achieving comprehensive resource utilization and clean production, further contributes to improved economic efficiency.

Shouldering the heavy responsibility, pioneering the new field of "microbial protein"

Microbial protein uses renewable biomass raw materials as substrates and is produced by cultivating microorganisms in fermentation tanks. Alternative protein can use advanced biotechnology to produce high-quality protein, making it an organic supplement and alternative to traditional animal protein sources, and is a new energy source in the food industry.

As the first company in China to achieve ton-scale industrialization of filamentous fungal protein, Fushine Pharmaceuticals currently boasts an annual production capacity of 1,200 tons, achieving industrialized production. Its technological level and production capacity are both leading domestically and internationally, achieving a leap forward in both quantity and quality. In the future, in line with market demand and industry development trends, the company aims to achieve a massive annual production capacity of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer. The company will continue to develop new production capacity and expand its microbial protein business, striving to achieve national self-reliance and self-reliance in synthetic biology.

In terms of core strains, the company has developed a new production strain, Fusarium brevicaulis, with completely independent intellectual property rights. The company has applied for patents in nine countries and regions, including China, continuously strengthening its core competitiveness in the field of microbial protein.

In terms of technological innovation, the company's "Key Technologies and Industrial Applications for Producing Microbial Protein by Fermentation of Fusarium brevis" project has passed the appraisal of the China Light Industry Federation. The overall technology of the project has reached the international advanced level, and it is recommended to increase efforts to promote its application.

In terms of industry status and market expansion, the company is a pioneer and leader in the domestic microbial protein industry. Not only did it host the first National Microbial Protein Technology Innovation and Industry Development Conference, and sign cooperation agreements with representatives of other industry partners in the field of microbial protein food and beverage applications, but it has also received invitations from numerous major domestic and international food companies and leading companies in healthy new diets to jointly advance microbial protein product development and market promotion, empowering future industry growth.

At the same time, we adhere to a strict quality management system and strive for steady progress. We comprehensively guarantee the quality of our products through a combination of internal and external audits. We regularly conduct internal audits of our quality management system in strict accordance with relevant guidelines of ICHQ7, GMP, ISO9001, FDA and EDDQM, and employ third-party external audits. This two-pronged approach establishes and improves our safety production management system.

Being selected as one of the "Outstanding Cases of Social Responsibility of Chinese Private Enterprises" is not only a recognition of Fushine Pharmaceuticals' efforts in social responsibility, but also a spur and encouragement for the company's future development. Fushine Pharmaceuticals will take this opportunity to further deepen its social responsibility philosophy, continuously innovate its social responsibility practices, and continue to play a leading role in demonstrating and inspiring more private enterprises to actively fulfill their social responsibilities, thereby jointly promoting the prosperity and development of China's economy and the harmonious progress of society.

"Mission is about responsibility, and struggle creates the future." Fushine Pharmaceuticals will continue to focus on its future development strategy, focusing on its three business segments: pharmaceutical manufacturing, new energy materials, and bio-fermentation. In the future, the company will continue to be driven by research and development, deeply implementing its mission of "Carefully Making Medicines, Protecting Health," and striving to become a more outstanding private enterprise and a more advanced global pharmaceutical company, making greater contributions to the health of China and humanity.